Journal of Patient-Reported Outcomes (Jul 2023)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis

  • James Twiss,
  • Diane Whalley,
  • Lynda Doward,
  • Maria-Magdalena Balp,
  • Clifford A. Brass,
  • Donna Cryer,
  • Arun Sanyal,
  • Quentin M. Anstee

DOI
https://doi.org/10.1186/s41687-023-00589-5
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Standardized measures for evaluating patients’ experiences with nonalcoholic steatohepatitis (NASH) and their perceived changes with treatment in clinical trials have been limited. To meet this need, a patient-reported outcome (PRO) measure, NASH-CHECK, was developed to evaluate symptoms and health-related quality of life for patients with NASH. The objective of this study was to conduct a quantitative evaluation of the psychometric properties of NASH-CHECK. Methods The study used data from a phase 2, randomized controlled trial of adult patients with NASH (NCT02855164). Analyses were conducted to determine the optimal scoring of NASH-CHECK and to evaluate reliability, construct validity, and ability to detect change in NASH-CHECK scale scores. Results Data were available for 253 patients with NASH (61% female; mean [standard deviation] age = 53 [12] years). Following initial item-level analyses, including correlations and exploratory factor analysis, three items were removed from the measure. Confirmatory factor analysis supported the formation of four multi-item scales (Cognitive Symptoms, Activity Limitations, Social Impact, and Emotional Impact) and five single-item scales (Abdominal Pain, Abdominal Bloating, Fatigue, Sleep, and Itchy Skin). Psychometric analyses of the final NASH-CHECK scales provided support for their internal reliability, test–retest reliability, construct validity, and ability to detect change. Conclusion The results support NASH-CHECK as a reliable, valid, and responsive measure to assess patients’ perspectives of symptoms and the health-related quality of life impact of NASH in clinical trials and in routine practice.

Keywords